Lynparza & Imfinzi positive CHMP in endometrial
1 July 2024 Lynparza and Imfinzi combination recommended for approval in the EU by CHMP for patients with mismatch repair proficient advanced or recurrent endometrial cancer Imfinzi also recommended for patients with mismatch repair deficient disease Recommendation based on DUO-E Phase III results, which showed both regimens demonstrated statistically significant and clinically meaningful improvement in progression-free survival vs. chemotherapy alone AstraZeneca's Imfinzi (durvalumab) and Lynparza (olaparib) have been recommended for approval in the European Union (EU) as